Intangible Assets

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible Assets

Intangible assets as of September 30, 2023 and December 31, 2022 consist of the following (in $000’s):

	September 30, 2023		December 31, 2022
Patent and domains	$	4	$	4
Soin intangibles *	$	19,293	$	19,293
Computer software	—		3,563
Intangible assets from discontinued operations	—		735
Intangible assets	19,297		23,595
Less accumulated amortization	(1,089)		(3,563)
Total intangible assets	$	18,208	$	20,032

*The Soin intangibles acquired by the Company consist of the following:

1.Three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain;

2.Final formula for Naltrexone; and

3.Orphan drug designation as approved by the FDA.

Intangible amortization expense from continuing operations was $363,000 and $0 for the 13 weeks ended September 30, 2023 and October 1, 2022 and $1.1 million and $0 for the 39 weeks ended September 30, 2023 and October 1, 2022.